Page 53 - 87_01

ANALES 99. Ahmad R, Alaei S, Omidian H. Safety and performance of current
RANF abuse- deterrent formulations. Expert Opin Drug Metab Toxicol. 2018
Dec 2;14(12):1255–71.
www.analesranf.com
100. Kopecky EA, Fleming AB, Levy-Cooperman N, O’Connor M, M. Sellers
Vol. 107, Advanced Drug Delivery Reviews. Elsevier B.V.; 2016. p. E. Oral Human Abuse Potential of Oxycodone DETERx®
213–27. (Xtampza® ER). J Clin Pharmacol. 2017;57(4):500–12. 101.Di-
85. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bige- vins M. Información de mercado. Analgésicos opiáceos. 2012;26.
low GE, et al. Extended-release injectable naltrexone for opioid use
disorder: a systematic review. Addiction. 2018 Jul 1;113(7):1188– 101. Divins M. Información de mercado. Analgésicos opiáceos. 2012;26.
209.
86. Elliott W, Chan J. Buprenorphine Implant for Subdermal Adminis- Si desea citar nuestro artículo:
tration (Probuphine). Intern Med Alert. 2016;93–4. Sistemas de liberación prolongada de opioides:
87. Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P,
Brousse G, et al. Prolonged-release buprenorphine formulations: analgesia y dependencia
Perspectives for clinical practice. Therapies. 2020 May Alexandre Pérez-López, Laura Gómez-Lázaro, et al.
1;75(5):397–406.
88. Goodbar NH, Hanlon KE. Implantable Buprenorphine (Probuphine) An Real Acad Farm [Internet].
for Maintenance Treatment of Opioid Use Disorder. Am Fam Physi- An. Real Acad. Farm. Vol. 87. Nº 1 (2021) · pp. 35 - 51
cian. 2018;97(10):668–70.
89. Park K, Otte A. Prevention of Opioid Abuse and Treatment of Opioid DOI: http://
Addiction: Current Status and Future Possibilities. Annu Rev Biomed
Eng. 2019 Jun 4;21(1):61–84.
90. Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist
therapy: Qualitative study exploring patients’ views of 1-week, 1-
month, and 6-month buprenorphine formulations. Harm Reduct J.
2019 Apr 3;16(1):25.
91. Malik K, Singh I, Nagpal M. Atrigel: A potential parenteral controlled
drug delivery system. Der Pharm Sin. 2010;1(1):74–81.
92. Heidbreder C. Driving innovation, strengthening our leadership pro-
file.
93 .Lofwall MR, Walsh SL, Nunes E V., Bailey GL, Sigmon SC, Kampman
KM, et al. Weekly and monthly subcutaneous buprenorphine depot
formulations vs daily sublingual buprenorphine with naloxone for
treatment of opioid use disorder a randomized clinical trial. JAMA
Intern Med. 2018 Jun 1;178(6):764–73.
94. Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A,
Brousse G, et al. What place for prolonged-release buprenorphine
depot-formulation Buvidal® in the treatment arsenal of opioid de-
pendence? Insights from the French experience on buprenorphine.
Expert Opin Drug Deliv. 2019 Sep 2;16(9):907–14.
95. Lintzeris N, Dunlop A, Masters D. Clinical guidelines for use of depot
buprenorphine ( Buvidal ® and Sublocade ® ) in the treatment
of opioid dependence. 2019. 1–56 p.
96. López-Muñoz F, García-García P, Alamo González C. Trastornos adic-
tivos. 231–268 p.
97. Chai G, Xu J, Osterhout J, Liberatore MA, Miller KL, Wolff C, et al.
New Opioid Analgesic Approvals and Outpatient Utilization of Opioid
Analgesics in the United States, 1997 through 2015. Anesthesio-
logy. 2018 May 1;128(5):953–66.
98. Chowdhury BA. Summary Review Of Regulatory Action-Incruse
Ellipta. 2014.

Sistemas de liberación prolongada de opioides: 51
analgesia y dependencia

Alexandre Pérez-López, Laura Gómez-Lázaro, et al.
An. Real Acad. Farm. Vol. 87. Nº1 (2021) · pp. 35 - 51